<DOC>
	<DOCNO>NCT00930631</DOCNO>
	<brief_summary>The purpose clinical study ass safety , extent route [ 3H ] BMS747158 radioactivity eliminate ( mass balance ) urine feces healthy male subject . The safety [ 3H ] BMS747158 administration also assess , well pharmacokinetics [ 3H ] BMS747158 metabolite identification .</brief_summary>
	<brief_title>Study 3H BMS747158 Healthy Male Subjects</brief_title>
	<detailed_description>This Phase I , nonrandomized , open-label study enroll seven healthy male subject meet inclusion none exclusion criterion . Subjects receive 100 ( ±20 ) μCi [ 3H ] BMS747158 . Subjects undergo blood , urine , fecal collection evaluate [ 3H ] activity minimum 7 day post-dose . Safety assess monitor adverse event ( AEs ) , vital sign , physical examination , clinical laboratory test , electrocardiogram ( ECGs ) .This Phase I , nonrandomized , open-label study enroll seven healthy male subject meet inclusion none exclusion criterion . Subjects receive 100 ( ±20 ) μCi [ 3H ] BMS747158 . Subjects undergo blood , urine , fecal collection evaluate [ 3H ] activity minimum 7 day post-dose . Safety assess monitor adverse event ( AEs ) , vital sign , physical examination , clinical laboratory test , electrocardiogram ( ECGs ) .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Provide write sign informed consent prior study procedure 2 . Be healthy determine clinically significant deviation normal medical history , physical examination , vital sign , ECG , clinical laboratory test 3 . Have Body Mass Index ( BMI ) 18 30 kg/m2 4 . Be male , age 18 45 year 5 . Be sterile agree use admission discharge one follow approve method contraception : male condom spermicide sterile sexual partner use female sexual partner intrauterine device ( IUD ) spermicide *a female condom spermicide contraceptive sponge spermicide intravaginal system [ e.g. , NuvaRing® ] diaphragm spermicide cervical cap spermicide , oral , implantable , transdermal , injectable contraceptive 6 . Must able communicate effectively study personnel 1 . Any significant active chronic medical illness acute significant trauma 2 . History condition may disrupt and/or increase permeability bloodbrain barrier diabetes 3 . History neurological disease . 4 . History concussion meningitis within past 6 month 5 . History sleep disorder , include snore sleep apnea narcolepsy 6 . History anxiety disorder 7 . Current recent GI disease 8 . Major surgery within 4 week 9 . GI surgery could impact upon reabsorption study drug 10 . History chronic constipation 11 . History asthma deem clinically significant Investigator designee 12 . History recent ( within 2 week enrollment ) infection ( e.g. , upper respiratory tract infection , urinary tract infection ) 13 . Known confirmed drug allergy hypersensitivities 14 . Donation blood and/or plasma blood bank clinical study ( except require screening ) within four week enrollment 15 . Blood transfusion within four week enrollment 16 . Inability tolerate intravenous medication unlikely obtain and/or tolerate venous access 17 . Past ( 6 month ) present history drug alcohol abuse 18 . Screening predose ECG interval abnormality organ dysfunction . 19 . Positive urine screen drug abuse either screen dose 20 . Positive blood screen hepatitis B surface antigen , hepatitis C antibody , HIV 21 . Exposure investigational drug , device , placebo within four week enrollment 22 . Use prescription drug within 4 week enrollment 23 . Use drug , include overthecounter medication ( e.g. , acidcontrollers ) herbal preparation within two week enrollment 24 . Smoking within 1 month enrollment 25 . Alcohol caffeine consumption within 72 hour study drug administration 26 . Participation radiolabeled study within 12 month enrollment 27 . Intake radiolabeled drug substance exposure significant radiation 28 . Participation prior study BMS747158</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>CAD</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>BMS747158</keyword>
</DOC>